Clinical trials
Hemophilia B trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
52 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2005 | 3 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 5 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 2 |
| 2017 | 5 |
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 37 |
| Recruiting | 6 |
| Terminated | 3 |
| Active, not recruiting | 2 |
| Enrolling by invitation | 2 |
| Not yet recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novo Nordisk A/S | 14 |
| CSL Behring | 10 |
| Pfizer | 5 |
| ApcinteX Ltd | 3 |
| Bayer | 2 |
| Bioverativ Therapeutics Inc. | 2 |
| Genzyme, a Sanofi Company | 2 |
| Regeneron Pharmaceuticals | 2 |
| Swedish Orphan Biovitrum | 2 |
| Wyeth is now a wholly owned subsidiary of Pfizer | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hemophilia B | 52 |
| Hemophilia A | 24 |
| Hematologic Diseases | 5 |
| Blood Coagulation Disorders | 4 |
| Blood Coagulation Disorders, Inherited | 3 |
| Coagulation Protein Disorders | 3 |
| Genetic Diseases, Inborn | 3 |
| Hemorrhage | 3 |
| Hemorrhagic Disorders | 3 |
| Fatigue | 2 |
Trials
Showing 1 to 25 of 52. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.